Supernus, Inc. (SUPN) stock
SUPNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$29.04+0.21 (+0.73%)
Close on Nov 17, 2026Market cap $3.43BP/E 8.1Yield –
Supernus operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Supernus's operating income for the twelve months ending Sep 30, 2026 was $558.00M, up 145.8% year over year. For fiscal 2025 it was $262.00M, up 589.5% from the year before. The highest annual figure on record is $262.00M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $262.00M | +589.5% |
| FY2024 | Dec 31, 2024 | $38.00M | – |
| FY2023 | Dec 31, 2023 | -$152.00M | – |
| FY2022 | Dec 31, 2022 | -$77.00M | -136.2% |
| FY2021 | Dec 31, 2021 | $213.00M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $180.00M | +318.6% |
| Q2 FY2026 | Jun 30, 2026 | $160.00M | +122.2% |
| Q1 FY2026 | Mar 31, 2026 | $137.00M | +107.6% |
| Q4 FY2025 | Dec 31, 2025 | $81.00M | +76.1% |
| Q3 FY2025 | Sep 30, 2025 | $43.00M | +22.9% |
| Q2 FY2025 | Jun 30, 2025 | $72.00M | – |
| Q1 FY2025 | Mar 31, 2025 | $66.00M | -12.0% |
| Q4 FY2024 | Dec 31, 2024 | $46.00M | – |
| Q3 FY2024 | Sep 30, 2024 | $35.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$118.00M | – |
| Q1 FY2024 | Mar 31, 2024 | $75.00M | – |
See a number that looks wrong?